NCT02325440View on ClinicalTrials.gov

Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya

PHASE4UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Fingolimod

Fingolimod: 0.5 mg p.o. (o.i.d)

DRUG

Natalizumab

Natalizumab: 300 mg i.v. (once at baseline);

Trial Locations (1)

48149

RECRUITING

Universitaetsklinikum Muenster, Department of Neurology, Münster

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital Muenster

OTHER